0
Summaries for Patients |

Improvement in Liver Fibrosis in Patients with Hepatitis C Who Respond to Interferon Treatment FREE

[+] Article and Author Information

The summary below is from the full report titled “Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy.”. It is in the 4 April 2000 issue of Annals of Internal Medicine (volume 132, pages 517-524). The authors are Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, O. Yokosuka, T. Kuroki, S. Nishiguchi, M. Sata, G. Yamada, S. Fujiyama, H. Yoshida, and M. Omata.


Ann Intern Med. 2000;132(7):517. doi:10.7326/0003-4819-132-7-200004040-00036
Text Size: A A A

What is the problem and what is known about it so far?

When viewed under a microscope, liver tissue damaged by chronic infection with the hepatitis C virus shows inflammation. As the disease progresses, scarring (fibrosis) occurs. This scarring can eventually cause a condition called cirrhosis, which can lead to liver failure. In some patients, treatment with a drug called interferon eliminates the virus. Doctors can now measure the amount of virus in patients' blood. Patients who have no measurable amount of virus in their blood 6 months after interferon treatment are generally considered to have responded well to the drug. Preliminary studies suggest that patients who respond to interferon treatment have improvements in liver inflammation. It is not known, however, whether fibrosis also improves with interferon treatment.

Why did the researchers do this particular study?

To find out what happens to liver fibrosis in patients with chronic hepatitis C who respond to interferon treatment.

Who was studied?

The researchers studied 593 patients with chronic hepatitis C who happened to have at least two liver biopsies during 1987-1998. Liver biopsy involves inserting a needle through the skin into the liver to obtain samples of tissue. Of these patients, 487 had interferon treatment and 106 had no treatment.

How was the study done?

The researchers judged the amount of fibrosis on each liver biopsy sample. Next they compared what happened to the fibrosis between the first and the follow-up biopsies in patients that responded to interferon, in those who got interferon but did not respond, and in untreated patients.

What did the researchers find?

Of the 487 patients who got interferon, the virus was eliminated for at least 6 months in 183 but was not eliminated in the other 304. However, scarring improved in 108 of the 183 (59%) of the patients who responded to interferon. Fibrosis improved in only 57 of the 304 patients (19%) who got interferon but did not respond to it. Of the 106 patients who had no interferon treatment, the fibrosis improved in only 5 (5%).

What were the limitations of the study?

Patients were not selected randomly to receive interferon, so the patients who got interferon may have been less severely ill in the first place than those who did not get it. The time between biopsies varied from 1 to 10 years, which makes it hard to compare the results in different patients. In addition, improvements in fibrosis seen under the microscope do not necessarily mean that patients will feel better, have better liver function, or live longer than patients who have no improvements in fibrosis.

What are the implications of the study?

It appears that liver fibrosis can improve in some patients with chronic hepatitis C who show elimination of the virus 6 months after interferon treatment.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)